All figures cover the European funds tracked here since 1 January 2025, whether closed or still raising, and are compiled from public sources.
Tracked funds
3
Reported volume
€897m
Latest public closing
28 Sept 2026
Reported volume sums the public fund amounts tracked here, not the manager's firm-wide assets under management, so it may differ from totals on the manager's website.
Sofinnova Partners is a European venture capital firm focused on life sciences, healthcare and sustainability. It invests from seed through later stages.
Focus: Life sciences, healthcare and sustainability, from seed to later stage
In 2021, Sofinnova said its €445m Crossover Fund was Europe's largest dedicated fund for late-stage biopharma and medtech scale-ups (company statement).